After completing 6 cycles of docetaxel plus ADT for metastatic hormone-sensitive prostate cancer per CHAARTED, are there clinical scenarios in which you would add an additional AR targeted agent (ex: enzalutamide, abiraterone, or apalutamide) to ADT?

Topics: Genitourinary Cancers • Prostate Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Johns Hopkins • NCI-CCC GU Tumor Board Question

Does post docetaxel PSA influence your decision?

Answer from: Medical Oncologist at Academic Institution

This is an important question and has in part been asked as part of subgroup analyses of the phase 3 ENZAMET, ARCHES, and TITAN mHSPC trials. In these trials, there was clinical benefit observed with combined chemohormonal therapy AND potent AR inhibition, sequentially in ARCHES/TITAN, and in combin...

Comments

Medical Oncologist at Sweetwater Regional Medical Center
Would you do that if they had failed these drugs (...

Related Questions